ribosomal protein S15aGenealiases: DBA20 · S15a · uS8
Q-omics provides the consensus-scored RPS15A profile across patient tissues and cancer cell-line models. RPS15A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPS15A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RPS15A protein abundance shows 21,576 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, KIRC, and BRCA as cancer lineages where RPS15A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS15A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS15A survival associations across molecular data types. RPS15A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS15A RNA expression–survival associations across cancer types. High RPS15A expression shows unfavorable associations in KIRP, ACC, LIHC, STAD and PAAD, but favorable associations in LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPS15A RNA expression.
This table summarizes RPS15A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPS15A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS15A shows lower tumor expression in BRCA and higher tumor expression in KIRC, KIRP, LIHC, COAD and CHOL. The KIRC box plot shows higher RPS15A RNA expression in tumor versus normal tissue (log2 FC = +0.924, t-test p < 0.001).
This table shows molecular features associated with RPS15A in patient tissues and cancer cell lines. In patient samples, RPS15A shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS15A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
